In vitro studies has shown that ALTILIX™ can counteract fat accumulation in hepatocytes cell line induced by free fatty acid.
The activity of ALTILIX™ has been evaluated in a randomized, double-blind, placebo-controlled clinical trial carried out:
• on 100 volunteers with metabolic syndrome at 3 different level of NAFLD
• treated with 150 mg/day of ALTILIX™
• for 6 months
ALTILIX™ supplementation showed statistically significant improvement of NAFLD (Fatty Liver Index) and other evaluated parameters including hepatic enzymes (AST, ALT, AST/ALT ratio), glucose metabolism parameters (HbA1c, HOMA-IR and HOMA-β), lipid profile (TC, TG and LDL-C), flow mediated dialation and Carotid intima-media thickness (cIMT).